Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US8106167B2 · kind B2 · utility
52Cited by
13References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2010 |
| Grant date | Jan 31, 2012 |
| Priority date | — |
| Expiry date | Aug 18, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2842
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.